DBV Technologies S.A. Total Assets 2011-2026 | DBVT

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets DBV Technologies S.A.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
65.7 M	183 M	247 M	147 M	272 M	241 M	172 M	178 M	288 M	343 M	125 M	46.2 M	43 M	15.7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
343 M	15.7 M	169 M

Quarterly Total Assets DBV Technologies S.A.

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
143 M	50.6 M	93.1 M	114 M	146 M	190 M	218 M	233 M	247 M	248 M	-	118 M	147 M	171 M	201 M	221 M	272 M	272 M	272 M	272 M	272 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
272 M	50.6 M	195 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
argenx SE ARGX	6.2 B	$ 834.06	0.94 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	1.3 B	$ 234.24	-0.3 %	$ 5 B	Danmark
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Aptorum Group Limited APM	16.1 M	$ 0.81	1.31 %	$ 4.42 M	China
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Atea Pharmaceuticals AVIR	465 M	$ 4.66	1.42 %	$ 393 M	USA
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Axsome Therapeutics AXSM	690 M	$ 167.61	-4.09 %	$ 8.34 B	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.33	0.79 %	$ 8.01 B	Australia
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
BioVie BIVI	21.6 M	$ 1.25	0.4 %	$ 1.85 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
BioMarin Pharmaceutical BMRN	6.99 B	$ 63.02	0.15 %	$ 12 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
CASI Pharmaceuticals CASI	138 M	$ 0.79	4.29 %	$ 108 M	USA
Catalyst Biosciences CBIO	117 M	$ 12.71	10.81 %	$ 837 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
Capricor Therapeutics CAPR	58.7 M	$ 27.89	0.07 %	$ 747 M	USA
Aptose Biosciences APTO	10.1 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
Aridis Pharmaceuticals ARDS	14.7 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	22.5 B	$ 110.88	0.86 %	$ 27.2 B	Germany
Amneal Pharmaceuticals AMRX	3.5 B	$ 14.72	2.08 %	$ 4.55 B	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Certara CERT	1.58 B	$ 6.67	2.77 %	$ 1.07 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Athira Pharma ATHA	58.8 M	-	-	$ 269 M	USA
Burford Capital Limited BUR	3.11 B	$ 9.32	1.25 %	$ 1.5 B	Britain
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
Autolus Therapeutics plc AUTL	783 M	$ 1.85	6.65 %	$ 472 M	Britain